Alector, Inc., a clinical-stage biotechnology firm specializing in neurodegenerative disease therapies, reported a net loss of $142.9 million for the year ended December 31, 2025, compared to a net loss of $119.0 million in 2024. The company's collaboration revenue decreased significantly from $100.6 million in 2024 to $21.0 million in 2025, primarily due to the satisfaction of performance obligations associated with the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in the fourth quarter of 2024. Research and development expenses also decreased, from $185.9 million in 2024 to $123.1 million in 2025, mainly due to the termination of the AL002 program and reductions in personnel-related costs following workforce reductions.
As of December 31, 2025, Alector's cash, cash equivalents, and marketable securities totaled $256.0 million, which the company anticipates will fund operations through at least 2027. The company's strategy involves developing product candidates that address neurodegenerative diseases through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. A key operational development is the ongoing Phase 2 clinical trial for nivisnebart in early Alzheimer's disease, with trial completion expected in 2026 and an independent interim futility analysis planned for the first half of 2026.
Alector is also advancing preclinical programs, including a brain-penetrant anti-amyloid beta antibody for Alzheimer's disease and a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease. The company is leveraging its Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier delivery technology, to improve central nervous system exposure across multiple therapeutic modalities. The company initiated a reduction in force in October 2025, impacting approximately 47% of its workforce, to align resources with strategic priorities following the results of the Phase 3 INFRONT-3 clinical trial for latozinemab.
The company's future success depends on the successful development, regulatory approval, and commercialization of its product candidates. Alector faces substantial competition from other pharmaceutical and biotechnology companies, and its product candidates are subject to extensive regulatory requirements. The company's ability to use its net operating loss carryforwards and certain other tax attributes may be limited. The market price of Alector's common stock may continue to be volatile, and sales of substantial amounts of its common stock in the public markets could cause the market price to decline significantly.
About Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company focused on developing genetically validated therapies for neurodegenerative diseases. Its core business involves creating monoclonal antibodies and biologics that elevate progranulin levels and target toxic proteins to restore brain cell function. Leveraging proprietary blood-brain barrier technology, Alector aims to enhance therapeutic delivery for conditions like frontotemporal dementia, Alzheimer’s, and Parkinson’s diseases, serving patients with high unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.